Jazz Pharmaceuticals Public Limited Company JAZZ

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the pharmaceuticals industry, including Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers.

On September 15, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) completed its acquisition of privately held Actio Biosciences for $820 million upfront, adding a clinical-stage epilepsy drug called ABS-1230 to its rare disease pipeline. The deal lands weeks after Jazz posted its highest quarterly revenue ever on August 3, and raised its full-year guidance, so a fresh acquisition […]

Jazz Pharmaceuticals (NasdaqGS:JAZZ) is assessing new trials of newly approved cancer drug Ziihera beyond gastroesophageal adenocarcinoma. The company is preparing development plans to study Ziihera in breast cancer, colorectal cancer, and lung cancer indications. Management is evaluating how broader Ziihera use could reshape Jazz Pharmaceuticals' long term oncology portfolio mix. The move to test Ziihera in breast, colorectal, and lung cancer only captures part of the story for Jazz. We...

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

Jazz Pharmaceuticals’s 29.7% return over the past six months has outpaced the S&P 500 by 17%, and its stock price has climbed to $240.49 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

Jazz Pharmaceuticals (JAZZ) could see long-term value from Ziihera's pursuit of additional indicatio

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.

Quoin has now received two rare paediatric disease designations for its lead asset QRX003.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) reported that Ziihera plus chemotherapy produced a statistically significant and clinically meaningful overall-survival benefit over trastuzumab plus chemotherapy in the Phase 3 HERIZON-GEA-01 trial. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) said the overall-survival hazard ratio improved from the first interim analysis, when the result favored Ziihera but was not statistically significant. The global, […]

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences:

RAPPERSWIL, SWITZERLAND - September 1, 2026 (NEWMEDIAWIRE) - Neovii Pharmaceuticals AG today announced the appointment of Duncan Ferguson as Chief Commercial Officer (CCO), effective 1 September 2026. Ferguson joins the company at a pivotal stage...